F
Fernando Civeira
Researcher at University of Zaragoza
Publications - 290
Citations - 9090
Fernando Civeira is an academic researcher from University of Zaragoza. The author has contributed to research in topics: Familial hypercholesterolemia & Population. The author has an hindex of 41, co-authored 263 publications receiving 7793 citations. Previous affiliations of Fernando Civeira include Carlos III Health Institute & Montreal Heart Institute.
Papers
More filters
Journal ArticleDOI
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial
Frederick J. Raal,Evan A. Stein,Robert Dufour,Traci Turner,Fernando Civeira,Lesley J. Burgess,Gisle Langslet,Russell S. Scott,Anders G. Olsson,David R. Sullivan,G. Kees Hovingh,Bertrand Cariou,Ioanna Gouni-Berthold,Ransi Somaratne,Ian Bridges,Rob Scott,Scott M. Wasserman,Daniel Gaudet +17 more
TL;DR: In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo.
Journal ArticleDOI
Cardiovascular efficacy and safety of bococizumab in high-risk patients
Paul M. Ridker,James H. Revkin,Pierre Amarenco,Robert Brunell,Madelyn Curto,Fernando Civeira,Marcus Flather,Robert J. Glynn,Jean Gregoire,J. Wouter Jukema,Yuri Karpov,John J.P. Kastelein,Wolfgang Koenig,Alberto J. Lorenzatti,Pravin Manga,Urszula Masiukiewicz,Michael Miller,Arend Mosterd,Jan Murin,Jose C. Nicolau,Steven E. Nissen,Piotr Ponikowski,Raul D. Santos,Pamela F. Schwartz,Handrean Soran,Harvey D. White,R. Scott Wright,Michal Vrablík,Carla Yunis,Charles L. Shear,Jean-Claude Tardif +30 more
TL;DR: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococzumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower‐risk patients but did have a significant benefit in the Trial involving higher‐risk Patients.
Journal ArticleDOI
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.
TL;DR: These guidelines have been elaborated by a group of international experts with the intention to answer the main questions about heterozygous FH (heFH) subjects that physicians worldwide face in the diagnosis and management of these patients.
Journal ArticleDOI
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance : The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab
Erik S.G. Stroes,David Colquhoun,David R. Sullivan,Fernando Civeira,Robert S. Rosenson,Gerald F. Watts,Eric Bruckert,Leslie Cho,Ricardo Dent,Beat Knusel,Allen Xue,Rob Scott,Scott M. Wasserman,Michael Rocco +13 more
TL;DR: Robust efficacy combined with favorable tolerability makes evolocumab a promising therapy for addressing the largely unmet clinical need in high-risk patients with elevated cholesterol who are statin intolerant.
Journal ArticleDOI
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
John J.P. Kastelein,Henry N. Ginsberg,Gisle Langslet,G. Kees Hovingh,Richard Ceska,Robert Dufour,Dirk J. Blom,Fernando Civeira,Michel Krempf,Christelle Lorenzato,Jian Zhao,Robert Pordy,Marie T. Baccara-Dinet,Daniel A. Gipe,Mary Jane Geiger,Michel Farnier +15 more
TL;DR: In patients with HeFH and inadequate LDL-C control at baseline despite maximally tolerated statin ± other LLT, alirocumab treatment resulted in significant LDL- C lowering and greater achievement of cholesterol-lowering target levels and was well tolerated.